Stock 4183 EPS BIO TECHNOLOGY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials EPS Bio Technology Corp.

Equities

4183

TW0004183009

Medical Equipment, Supplies & Distribution

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
26.2 TWD +0.58% Intraday chart for EPS Bio Technology Corp. -2.60% -0.95%
05-14 EPS Bio Technology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-20 EPS Bio Technology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 343.9 466.5 509.3 437.9 440.3 629.5
Enterprise Value (EV) 1 177 427.8 419.4 361 383 550
P/E ratio 21.9 x 25.5 x 16.1 x 23.6 x 17.5 x 30.1 x
Yield 4.84% 3.57% 5.61% 3.8% 5.3% 3.02%
Capitalization / Revenue 0.83 x 1.02 x 1.07 x 0.91 x 0.95 x 1.34 x
EV / Revenue 0.43 x 0.93 x 0.88 x 0.75 x 0.83 x 1.17 x
EV / EBITDA 7.28 x 10.9 x 7.3 x 7.68 x 13.3 x 15.3 x
EV / FCF -16.8 x -863 x 6.62 x 23.7 x -17.2 x 13.8 x
FCF Yield -5.94% -0.12% 15.1% 4.23% -5.83% 7.26%
Price to Book 1.18 x 1.59 x 1.65 x 1.46 x 1.43 x 2.06 x
Nbr of stocks (in thousands) 23,800 23,800 23,800 23,800 23,800 23,800
Reference price 2 14.45 19.60 21.40 18.40 18.50 26.45
Announcement Date 4/1/19 3/24/20 3/24/21 3/28/22 3/28/23 3/20/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 414.2 459.3 477.6 480.3 463.5 470.2
EBITDA 1 24.29 39.08 57.41 47.01 28.72 35.9
EBIT 1 9.839 27.73 44.16 33.06 16.01 24.92
Operating Margin 2.38% 6.04% 9.25% 6.88% 3.46% 5.3%
Earnings before Tax (EBT) 1 17.81 24.01 40.07 23.52 27.46 26.46
Net income 1 15.8 18.44 31.7 18.64 25.36 20.99
Net margin 3.81% 4.01% 6.64% 3.88% 5.47% 4.46%
EPS 2 0.6600 0.7700 1.330 0.7800 1.060 0.8800
Free Cash Flow 1 -10.51 -0.4955 63.31 15.26 -22.31 39.95
FCF margin -2.54% -0.11% 13.26% 3.18% -4.81% 8.5%
FCF Conversion (EBITDA) - - 110.28% 32.46% - 111.28%
FCF Conversion (Net income) - - 199.73% 81.88% - 190.36%
Dividend per Share 2 0.7000 0.7000 1.200 0.7000 0.9800 0.8000
Announcement Date 4/1/19 3/24/20 3/24/21 3/28/22 3/28/23 3/20/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 167 38.7 89.9 77 57.3 79.5
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -10.5 -0.5 63.3 15.3 -22.3 40
ROE (net income / shareholders' equity) 5.49% 6.29% 10.5% 6.13% 8.35% 6.83%
ROA (Net income/ Total Assets) 1.5% 3.62% 5.1% 3.67% 1.81% 2.91%
Assets 1 1,054 509.1 621.2 507.2 1,400 721.6
Book Value Per Share 2 12.30 12.40 13.00 12.60 13.00 12.90
Cash Flow per Share 2 8.180 7.390 9.320 8.550 7.510 8.210
Capex 1 14.2 14.8 6.49 11.7 15 9.48
Capex / Sales 3.43% 3.21% 1.36% 2.45% 3.23% 2.02%
Announcement Date 4/1/19 3/24/20 3/24/21 3/28/22 3/28/23 3/20/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
EPS BIO TECHNOLOGY CORP. Stock EPS Bio Technology Corp.
-0.95% 19.19M
BIOMÉRIEUX Stock bioMérieux
-11.78% 11.24B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-13.76% 7.29B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+29.50% 5.57B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-0.19% 5.31B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-19.19% 3.68B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+7.62% 2.58B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-65.24% 2.33B
VITROLIFE AB Stock Vitrolife AB
-10.48% 2.23B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+27.80% 2.21B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 4183 Stock
  4. Financials EPS Bio Technology Corp.